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The purpose ofthis workshop was to bring
together the collective experience of many
disciplines to discuss and evaluate tech-
niques for the detection offunctional estro-
genicity. Estrogenicity was first defined as a
physiological response to a compound that
induced estrus in vivo. The bioassay for
induction ofestrus developed into a utero-
tropic assay. The classical tissue response
evaluated in this assay was an estrogen-
induced increase in wet weight and tissue
mass. Tissue response follows a time course
ofstimulation, including an earlyphase at 2
to 4 hr, followed by a second later phase. A
higher dose of compound generates a
stronger response. Weak estrogens exhibit
the early response phase, but then the
response falls off; however, multiple low
doses of weak estrogens mimic the full
activity of strong estrogens. A host of
chemical and molecular biological factors
are involved in the uterotropic response.
Gene Activation
Hormone receptor mechanisms exist-
both membrane and nuclear receptor path-
ways-that affect gene regulation and
interact with one another. Certain genes
are specifically regulated by estrogen acting
through the estrogen receptor (ER). These
effects appear to be mediated by the inter-
action of the estrogen/ER complex with
estrogen response elements (EREs) in regu-
latory regions ofthose genes. For instance,
the vitellogenin A2 estrogen-responsive
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sequence has been cloned and can be used
to detect and measure estrogen response.
The DNA sequence is closely analogous to
the sequence ofa glucocorticoid responsive
elementwith four base changes.
Korach's group (1) cloned an estrogen-
responsive sequence and inserted it into a
reporter gene vector. The construct became
an estrogen "inducible promoter" linked to
bacterial chloramphenicol acetyltransferase
(CAT), which can be detected in a trans-
fected cell to measure estrogen-related gene
activity. When an ER-positive target cell
such as MCF-7 is transfected with this
receptor-specific reporter-gene construct,
CAT expression can be measured following
estrogen treatment. In a test against a non-
responsive (ER negative) cell, transfection
with the receptor-specific reporter alone
does not lead to estrogen-induced CAT
expression. It must be transfected with ER
to get the hormonally induced CAT pro-
duction, demonstrating that the system is
specific for ER-mediated gene expression
and regulation. This system will respond to
treatment with stilbestrol estrogens with
CAT gene expression as well. Phospho-
imaging of the CAT gene product can be
used for easyquantitation.
Phytoestrogen compounds were tested
with this ERE-CAT construct-transfection
system. CAT stimulation by genistein,
coumestrol, and zearalenone was compared
with the stimulation produced byestradiol.
CAT induction by genistein was about
20% that of estradiol; coumestrol activity
was about the same; zearalenone produced
about 1.7-fold stimulation compared to
estradiol. The addition of a commercially
available estrogen antagonist (ICI 164,384)
resulted in almost complete inhibition of
CAT induction by these compounds. It is
important to keep in mind that the active
compound may be a metabolite that the
cell might not see in an in vitro assay but
which would show activity in vivo. Future
studies using different mutants of the
receptor can evaluate more precise regula-
torymechanisms.
The gold standard at this time is still the
mouse uterine bioassay, precisely because it
replicates a living situation and incorporates
the effects of metabolism, serum binding,
and pharmacokinetics. However, a com-
plete dose-response assay can be expensive
and time consuming; it is also a difficult
process for testing a large number ofchemi-
cals. In vitroassays maybe cheaper, quicker,
and more reproducible; however, the
difficulties already mentioned must be con-
sidered and dealt with to allow their use in
exposure studies and possible risk assess-
ments. A question was posed by a number
ofparticipants: How do we come up with a
way to design the best assays for screening
water or other contaminated sources to
determine estrogenic activity?
Proliferation Controls
The question that has guided the efforts of
Soto's laboratory in the area of prolifera-
tion has been how to screen for a variety of
chemicals quickly (2). It is important to
remember that environmental contami-
nants ofwidely diverse chemical structure
mimic estrogen actions. From a public
safety concern, estrogenicity should be
tested before chemicals are released into
the environment.
Screening should be based on the end
point of estrogenic action that has the
greatest physiological relevance. A crucial
end point can be based on the definition of
an estrogen promulgated by Roy Hertz in
1985 (3): an estrogen is a substance that
can elicit the mitotic stimulation ofthe tis-
sues of the female genital tract; therefore,
measuring cell proliferation is of key
importance in assessing estrogenicity. To
determine whether chemical "X" is an
estrogen, one must test its ability to induce
proliferation of estrogen-responsive target
cells, even though not all estrogen responses
or target tissues respond with proliferation.
The question of whether fish in lake
"Y or birds in region "Z" are exposed to
estrogenic xenobiotics can be answered at
an initial level of screening by examining
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endogenous vitellogenin (VTG) produc-
tion. When VTG levels are increased, the
next question is which chemicals caused
the observed estrogenic effects? To answer
this question, isolation and chemical analy-
sis are required. When dealing with com-
pounds that are not dassically described as
estrogens, a bioassay is necessary to evalu-
ate their estrogenicity. Estrogenicity cannot
be deduced solely from chemical structure.
The classic method for measuring estro-
gen induction of cell proliferation is to
determine the increase ofmitotic indices of
epithelia in rodents. As mentioned by
Korach, this is an accurate but labor-inten-
sive, time-consuming approach, totally
unsuitable for the screening oflarge num-
bers ofchemicals.
Soto et al. (2) have introduced a cell
proliferation assay termed the E-SCREEN
test. For this bioassay, MCF-7 breast can-
cer cells were chosen. These cells are gen-
uine human estrogen-sensitive cells; they
remain quiescent when inoculated into
ovariectomized hosts. They require the
presence of estrogen to grow as tumors in
hosts. When MCF-7 cells are grown in
culture in medium supplemented with
nonestrogenic charcoal-stripped human
serum, proliferation is prevented. When
estrogen is added, the cells proliferate. The
E-SCREEN assay compares the cell yield
achieved after 4 to 6 days of culture in
medium supplemented with 5 to 10%
charcoal-dextran stripped human serum
in the presence (positive control) or
absence (negative control) ofestradiol and
with diverse concentrations ofxenobiotics
suspected of being estrogenic. When cell
yield is examined over awide range oftest-
compound concentrations, it is possible to
distinguish agonists, partial agonists, and
inactive compounds from one another.
There is general agreement about cell yield
being a more sensitive marker than gene
expression. A 6-fold increase can be mea-
sured in cell yields after 5 days of expo-
sure; no false positives and no false
negatives have been found among the test
compounds of known estrogenicity.
Methoxychlor, which requires metabolic
activation, is positive in this assay; obvi-
ously, MCF-7 cells can provide the appro-
priate metabolic transformation. The
E-SCREEN cell-yield assay is easy to per-
form, requiring only standard eukaryotic
cell culture equipment plus an ELISA
reader or an electronic particle counter.
For regulatory purposes, an assay that is
biologically valid is needed; that is, the
end point examined should have wide but
unambiguous biological meaning.
McLachlan was concerned with the
binding proteins and whether they were
still present in the charcoal-stripped serum.
It appears that the binding proteins are pre-
sent (sex hormone-binding globulin
[SHBG] and serum albumin); however, a
significant amount of SHBG is denatured
during heat inactivation of serum (final
concentration in 10% charcoal-dextran
human serum is less than 3 nM (4).
Approximately 85% of estradiol is bound
to plasma proteins in this assay (5).
Screening for estrogens using males as a
model should not be done because estro-
gens are primarily defined by their ability
to increase the mitotic activity of female
secondary sex organs. There are reports of
effects on male fertility due to exposure to
estrogens. In males, estrogens are believed
to act via a negative feedback to inhibit
gonadotropins; this results in the lowering
of androgen production by Leydig cells
and inhibition ofspermatogenesis.
There is no endogenous estrogen in this
assay; we are measuring direct effects. An
enzyme inhibitor could be an effector ofan
estrogen response in a system where there
is a source ofestrogens, such as in any ani-
mal model. Moreover, this assay can be
used as a first screen for estrogenicity; any
positive response would require further
study to determine an underlying mecha-
nism ofaction.
It was pointed out by McLachlan that
in the 1930s CC14 was described as an
estrogen because ofthe enhanced estrogen-
like sequelae of CC14 administration. It
was later learned that these estrogenlike
effects occurred because of CC14 destruc-
tion of the liver, which resulted in
decreased turnover and an elevation ofthe
level ofestradiol in the circulation.
An MCF-7 variant has been modified
to grow in serum-free and nonestrogenic
medium by Briand et al. (6). This variant
behaves similarly in the E-SCREEN assay
when exposed to 10% charcoal-dextran
stripped human serum (estradiol [E2]
concentration in the medium is below
0.001 pg/ml; this is below 4 fM or about
1/1000 ofthe dose needed for the smallest
significant proliferative response). MCF-7
cells are exposed to practically no estrogen
in this "estrogenless" condition.
VFtellogenin as a Biomarker
Could a universal assay for vertebrate vitel-
logenins be used as a new test for environ-
mental estrogens? Sullivan described a
screen that defines an estrogen as something
that induces vitellogenesis [Heppell et al.,
this volume; (7)]. Vitellogenin is a classic
steroid-inducible protein; ifyou expose an
oviparous vertebrate to estrogen, it will syn-
thesize VTG. VTG is synthesized in the
liver under the control of estrogen. This
usually occurs in females but can also be
induced in males. VTG is taken up into the
oocyte by receptor-mediated endocytosis. It
is present in the plasma of females several
months before ovulation and is related to
cholesterol and mineral transporters. In
serum collected from brown bullhead,
Sullivan observed a massive induction of a
protein in tumor-bearing males and
females, which is not present in control
females; this induction appeared to be the
result of an environmental insult. The
induced protein was shown to be VTG by
N-terminal amino acidsequencing.
For the purposes of a universal assay,
VTG itself is hard to work with since it
varies in structure between species. So, the
paradigm includes creation of monoclonal
antibodies to vertebrate VTG. Sullivan's
group screened first for antibodies that rec-
ognize both rainbow trout and striped bass
VTGs. The second screen was against VTG
from fish, amphibians, and mammals. A
positive screening result from one clone
included cross-reactivity to VTG from bass,
perch, trout, tilapia, sturgeon, chicken,
tuatara, and platypus; there was a question-
able result in this assay for rartlesnake VTG
due to ahigh background.
Antibodies to specific portions of the
molecule can be generated. It is possible to
select conserved sequences, do structural
analysis, select a portion ofthe peptide that
seems likely to be on the outside in native
conformation, synthesize it and conjugate
it to carriers, generate antibodies, and
repeat first and second screens. The N-ter-
minal sequence ofstriped bass VTG shows
homology with various fish, amphibian,
and avian species. Demonstrated homol-
ogy was between 40 to 100%. Using VTG
and related proteins like von Willebrand
factor, you can generate an assay that
would be applicable across species from
fish to mammal.
The physiological significance of vitel-
logenesis in males is not known. VTG
receptors in the testes and in muscles in
males have been found, and VTG is found
in spermatocytes. VTG is a generic,
ancient lipoprotein; it is not surprising that
it is found in an abundance oftissues. The
VTG receptor might also be involved in
endocytosis ofother lipoproteins.
Lactoferrin as a Biomarker
What would be a good biomarker for
estrogenicity in mammals-similar to what
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Sullivan described in fish or reptiles (see
Heppell et al., this volume). Ideally, one
would choose a natural product ofthe cells
that is sensitive to estrogenic compounds,
one that is present in mammals-both
humans and wildlife, and one that is con-
venient to study, i.e., a well-characterized
estrogen-responsive protein or gene. Work
and studies described by Teng showed
that, ofthe 30 to 40 total uterine proteins,
one band makes up approximately 15% of
the total; this band is lactoferrin (LF). As
seen by immunolocalization, LF is made in
response to diethylstilbestrol (DES) treat-
ment. It is an iron-binding glycoprotein
with a molecular weight of 68 to 70 kDa.
It is a basic protein with a pI of 9 to 10
belonging to the transferrin gene family.
Lactoferrin has 2.6 kb mRNA; the gene is
33 kb in the human and 22 kb in the
mouse. LF's biological function is antibac-
terial and antiviral; it also has a growth-
stimulating factor activity. Low levels exist
in biological fluids and wet surface mucosa,
whereas high levels exist in neutrophils,
lactating mammary gland, and uterus. LF
is regulated under various control mecha-
nisms in different tissues. In the uterus, it
is inducible by estrogen. Looking at puta-
tive regulatory elements of the mouse
lactoferrin gene promoter region, Teng's
group identified and characterized an estro-
gen response element (8). More recently,
they found a response element that was
responsive to cAMP and epidermal growth
factor (EGF) (C Teng, this volume). LF
induction seems to be a complex interac-
tion, not a simple one-way cause and
effect. The human LF gene has an ERE in
the same location, but it also has some dif-
ferent response elements.
As pointed out by Adlercreutz, SHBG
is another potential marker. SHBG
increases when estrogens are given to
women orally but not ifthey are given par-
enterally; 200 nM estradiol is needed to get
this response, but with a weak estrogen,
much more may be needed. Several tests
have been made with enterolactone. Are
there any studies ofeffects of thyroxine or
insulin? Could other hormones have an
effect? SHBG is a good marker in females.
Another protein marker is ceruloplasmin
(CP), a copper-containing protein. Treat-
ment with a nonestrogenic oral contracep-
tive stimulates CP, which is also increased
in pregnancy.
Regarding estrogenicity, biology is a
hierarchical science whereby questions
should be answered at the same hierarchi-
cal level at which they are posed. Estrogens
were defined before the development of
molecular biology and the discovery ofthe
estrogen receptor. It is important to under-
stand mechanisms, but we are far from
agreeing on them. In the meantime, estro-
gens are reliably defined by their effect on
the female genital tract. Moreover, estrogens
exclusively induce cell proliferation in the
E-SCREEN assay. These same estrogens
also induce progesterone receptor and dis-
place estradiol from the estrogen receptor.
Toxicological Approaches
Toxicological approaches rely on the chem-
ical attributes of estrogens and use the
study ofthe carcinogenic effects ofDES as
a background. Investigators have asked
whether DES, acting as a carcinogen,
causes genetic damage. This approach has
been tested by Metzler's laboratory (9).
One sort of genetic change that has been
reported in many systems is aneuploidy or
altered chromosome numbers following
exposure to DES and other estrogens.
Furthermore, it has been shown that DES
has colchicinelike effects and disrupts
mitotic spindles. This suggests tubulin as a
possible additional target for estrogen
action and aneuploidy as a measure ofsuch
action. Metzler showed there are at least
two binding sites on the tubulin molecule:
one is the colchicine-binding site, which
can also be bound by DES; another bind-
ing site can be occupied by estradiol or by
DES but not by colchicine and has no
effect on microtubule assembly (MA) (9).
The assay for turbidity measures MA under
cell-free conditions. All stilbene estrogens
can bind and inhibit MA directly, but the
steroid estrogens and the phytoestrogen the
Metzler group has tested so far cannot bind
or inhibit MA. Some steroid estrogens are
inhibitory after metabolic activation.
Therefore, tubulin binding and MA dis-
ruptions are not estrogenic markers per se.
However, all the estrogens tested were posi-
tive in inducing micronuclei, an indication
of chromosomal damage. Coumestrol, the
only phytoestrogen tested so far, was also
active in micronuclei induction. The
mechanism may be different from effects
of compounds that are capable ofbinding
directly to tubulin and disrupting micro-
tubule assembly. Binding to tubulin itself
is not a biomarker, but many estrogens can
cause chromosomal damage by different
mechanisms.
This introduces the concept of bipolar
characteristics of estrogens. Some of the
same compounds, which may be more or
less weak estrogens, may have different
activities in spindle disruption or may
have other activities that have yet to be
discovered. Consider, in addition, another
factor-time or life stage of exposure.
17a-Estradiol does not cause uterine
growth in an adult, but exposure during a
critical period ofgrowth leads to manifold
effects including aneuploidy. 17a-Estradiol
is astrong effector in neonatal orfetal tissue.
Conclusion
At the end of the presentation and work-
shop, one of the participants posed two
overlying problems. First, if we are con-
cerned about exposure to the male, the crit-
ical period is in utero. Second, how does the
male fetus protect itself against estrogens,
either maternal or from other sources? We
have no answer right now. We need an
overall picture of how we are exposed
to estrogens, and we need a method to
determine our exactlevels ofexposure.
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